The ZENITH study looked at some of the sickest pulmonary arterial hypertension (PAH) patients—those labelled as functional class 3...

"A person's mental health significantly influences how they experience pain and suffering associated with chronic disease. It's essential...

We asked Liss Cairns, Program Manager at Plan Institute, some questions about the Disability Tax Credit and the new Canada Disability...

Living with a rare disease can feel like walking an unmarked path—isolated, uncertain, and overlooked. For those with pulmonary arterial...

The 2025 BC Medication Coverage Report  is here—and it reveals serious gaps in access to life-saving medications across the province....

There has been significant progress in making sotatercept available to those who need it. Just two months after Health Canada approved it...

Tax season is upon us! The pulmonary hypertension community brought two tips to our attention. First, the usual disclaimer: we are not...

New Report Sheds Light on Pulmonary Hypertension in Canada Respiplus has just released a groundbreaking report, A Canadian Initiative:...

Many people know about Canada’s Disability Tax Credit, but did you know that there is also a non-refundable tax credit for caregivers? If...

"Imagine being told that a new treatment exists — one that could save your life or significantly improve it — but that you’ll have to...

The holiday season is the most critical fundraising period for charities, with many relying on year-end donations to sustain their work....

In an innovative new collaboration between Trillium Gift of Life Network (TGLN) and the provincial and federal governments, millions of...

As of December 1, the Ontario government has improved reimbursement amounts for people in Northern Ontario who need to travel for...

A webinar hosted by the Pulmonary Hypertension Knowledge Sharing Platform this week talked about a couple of studies on mental health in...

💜 RDSP Awareness Month is almost over , but it’s not too late to learn about the benefits of a Registered Disability Savings Plan (RDSP)...

PHA Canada is proud to announce our latest submission to the Patented Medicines Pricing Review Board (PMPRB)  this September. As the...

Merck has announced that WINREVAIR® (sotatercept) is now authorized for use in Canada in combination with standard pulmonary arterial...

A new investigation, "A Canadian Initiative: Exploring Adult Pulmonary Hypertension," highlights critical issues such as diagnostic...

We are pleased to announce that sotatercept, a new drug for patients diagnosed with pulmonary arterial hypertension (PAH), is now listed...

This article originally appeared in The Hills Times on May 6, 2024 Have you ever tried to fix something without the right tool? If you...